CF
ALNY icon

Corebridge Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Corebridge Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,128
Closed -$575K – 125
2025
Q1 		$575K Sell
2,128
-81
-4% -$20.8K ﹤0.01% 1510
2024
Q4 		$520K Sell
2,209
-50
-2% -$13.2K ﹤0.01% 1666
2024
Q3 		$621K Sell
2,259
-81
-3% -$21.1K ﹤0.01% 1618
2024
Q2 		$569K Buy
+2,340
New +$369K ﹤0.01% 1623

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Corebridge Financial's ALNY Position: Q2 2025 in Review

Corebridge Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2025, closing a stake of 2,128 shares — an estimated $575K sold.

Corebridge Financial first reported a position in ALNY in Q2 2024 and held it in 4 quarters. The position peaked at $621K in Q3 2024. 654 funds tracked by Wall St. Rank hold ALNY as of Q2 2025.

  • Corebridge Financial reported no remaining Alnylam Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 2,128 Alnylam Pharmaceuticals shares in Q2 2025, an estimated $575K.
  • Corebridge Financial first reported a position in Alnylam Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Alnylam Pharmaceuticals position peaked at $621K in Q3 2024.
  • 654 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.